News
Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...
U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.
Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...
Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...
According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...
Merck (MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, becoming ...
The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...
Biopharmaceutical giant Merck (NYSE: MRK) has broken ground on a $1 billion pharmaceutical manufacturing facility in ...
Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...
It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.
2d
GlobalData on MSNConstruction begins on MSD’s $1bn biologics centre in Delaware, USMerck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results